Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 16/50 27/50; SQUAMOUS CELL CARCINOMA 0/50 12/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/51 16/50; SQUAMOUS CELL CARCINOMA 0/50 12/51 13/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 28/40 53/60 43/49; CARCINOMA 0/50 2/40 21/60 8/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP (ADENOMA) 0/50 13/40 51/59 40/50; CARCINOMA 0/50 1/40 11/59 17/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 3/40 16/60 16/48 OR CARCINOMA 0/50 0/40 0/60 2/48
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 10/40 11/59 14/50 OR CARCINOMA 0/50 0/40 2/59 1/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 45/50 49/50; CARCINOMA 0/50 23/50 27/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 38/51 39/50; CARCINOMA 9/50 18/51 21/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 28/40 47/60 29/48; CARCINOMA 0/50 12/40 57/60 45/48; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 11/60 13/48
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 20/40 40/59 34/50; CARCINOMA 1/50 12/40 55/59 46/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/40 6/59 2/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/50 17/50 13/49
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 7/50 26/51 24/50
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 2/40 7/60 9/46; TRANSITIONAL CELL CARCINOMA 0/50 0/40 8/60 16/46
|
Neoplastic Lesions
|
No
|
TR-383
|
81-49-2 |
1-Amino-2,4-dibromoanthraquinone |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/50 1/38 2/58 8/50; TRANSITIONAL CELL CARCINOMA 0/50 0/38 1/58 4/50
|
Neoplastic Lesions
|
Yes
|
TR-028
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-028
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-028
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
Osborne Mendel |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-028
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-028
|
96-12-8 |
1,2-Dibromo-3-chloropropane |
Rats |
Osborne Mendel |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-086
|
106-93-4 |
1,2-Dibromoethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
Yes
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Female |
Gavage |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Subcutaneous Tissue
|
Positive |
Positive |
(FIBROMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Positive |
Positive |
(POLYP, SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-055
|
107-06-2 |
1,2-Dichloroethane |
Rats |
Osborne Mendel |
Male |
Gavage |
Vascular System (Unspecified)
|
Positive |
Positive |
(HEMANGIOSARCOMA)
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/46 10/46 13/50 10/51 OR CARCINOMA 0/46 0/46 4/50 6/51 COMBINED 5/46 10/46 17/50 15/51
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 23/50 18/51 29/55; SQUAMOUS CELL CARCINOMA 0/50 46/50 49/51 49/55
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/52 28/51 22/54 33/56; SQUAMOUS CELL CARCINOMA 0/52 40/51 50/54 51/56
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 13/49 32/51 17/52; SQUAMOUS CELL CARCINOMA 0/50 3/49 9/51 4/52
|
Neoplastic Lesions
|
Yes
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 29/50 33/49 38/52; SQUAMOUS CELL CARCINOMA 0/50 9/50 27/49 13/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 6/50 7/51 10/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/52 2/51 10/54 11/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/49 0/47 1/52 2/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Intestines (Large)
|
Clear Evidence |
Equivocal Evidence |
ADENOCARCINOMA 0/50 0/50 2/48 1/52
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 20/49 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 6/50 9/50 8/51 31/55 OR CARCINOMA 1/50 3/50 0/51 2/55 COMBINED 7/50 11/50 8/51 31/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 11/52 18/51 21/54 29/56; CARCINOMA 13/52 24/51 24/54 31/56
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 1/50 6/49 12/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 0/51 0/54 2/56
|
May Have Been Related
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 0/50 1/51 5/55
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 5/49 10/52 18/52 ; SQUAMOUS CELL CARCINOMA 0/50 1/49 21/52 21/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 9/49 19/52; SQUAMOUS CELL CARCINOMA 1/50 0/50 11/49 25/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 21/50 36/49 29/52
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/49 3/47 5/49 11/50 OR CARCINOMA 0/49 3/47 3/49 5/50 COMBINED 5/49 6/47 8/49 16/50
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/51 3/54; ADENOCARCINOMA 0/50 4/50 3/51 6/54; POLYP 0/50 2/50 1/51 6/54
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Female |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 1/59 0/60 4/60
|
Neoplastic Lesions
|
No
|
TR-384
|
96-18-4 |
1,2,3-Trichloropropane |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/60 0/60 0/59 3/60
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Equivocal Evidence |
GLIOMA 0/50 2/48 1/49
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Brain
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) GLIOMA 0/50 2/50 0/50 1/50
|
Neoplastic Lesions
|
Yes
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 4/42 10/49
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 3/50 2/50 4/50 22/80
|
Neoplastic Lesions
|
Yes
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 1/50 0/50 0/50 1/50 8/50 4/73, STOP STUDY 3/50 7/50 9/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
PAPILLOMA 0/49 5/40 0/44
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 8/50 10/50 7/50 15/50 20/50 9/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 6/50 7/50 9/50 20/50 31/50 6/73, STOP STUDY 27/50 23/50 30/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 6/50 12/50 11/50 7/50 9/50 32/80; HISTIOCYTIC SARCOMA 3/50 2/50 7/50 4/50 7/50 4/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 1/50 10/49 10/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 0/50 23/50 29/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LYMPHOMA 4/50 2/50 4/50 6/50 2/50 51/73, STOP STUDY 8/50 22/50 8/50 33/50; HISTIOCYTIC SARCOMA 0/50 0/50 4/50 5/50 7/50 4/73, STOP STUDY 5/50 2/50 7/50 2/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50 1/50 2/50 0/73
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/49 0/48 0/50 2/50 0/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50 3/48 1/49 0/73, STOP STUDY 4/48 1/50 3/49 1/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 15/49 14/49 15/50 19/50 16/50 2/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/47 4/49 OR CARCINOMA 0/50 1/47 1/49 COMBINED 0/50 2/47 5/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 21/50 23/50 30/50 25/48 33/48 5/72, STOP STUDY 27/49 19/49 19/50 11/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 4/50 15/50 19/50 24/50 25/50 22/78
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/49 9/48 20/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/49 6/48 8/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/50 12/49 11/49; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 2/49 5/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA, ADENOCARCINOMA, OR CARCINOMA 21/50 23/50 19/50 31/49 35/50 3/73, STOP STUDY 36/50 28/50 32/50 17/50
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ACINAR CELL CARCINOMA 0/50 2/49 6/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA, ADENOCARCINOMA, OR MALIGNANT MIXED TUMOR 0/50 2/50 4/50 12/50 15/50 16/80
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 1/49 0/49 1/48 9/50 8/50 6/79; ADENOMA OR BENIGN MIXED TUMOR 2/49 4/49 1/48 4/50 6/50 2/79
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Ovary
|
Clear Evidence |
Clear Evidence |
GRANULOSA CELL TUMOR 0/49 6/45 12/48
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL CARCINOMA 0/50 3/50 1/50
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 0/50 5/50 0/73, STOP STUDY 1/50 4/50 4/50 3/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Equivocal Evidence |
NEUROFIBROSARCOMA OR SARCOMA 1/50 2/50 3/50 5/50 3/50 3/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/50 0/50 1/49 21/50 23/80
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 11/48 18/49
|
Neoplastic Lesions
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 16/49 7/49
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Heart)
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/50 0/49 1/50 5/48 20/48 4/73, STOP STUDY 15/50 7/50 33/50 13/50
|
Neoplastic Lesions
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
ADENOMA OR CARCINOMA 0/50 0/50 0/50 0/50 0/50 2/80
|
May Have Been Related
|
No
|
TR-434
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
(STOP STUDY) CARCINOMA 1/50 0/50 2/50 2/50
|
May Have Been Related
|
No
|
TR-288
|
106-99-0 |
1,3-Butadiene |
Mice |
B6C3F1 |
Male |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 0/50 2/50
|
May Have Been Related
|
Yes
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 1/52 9/52; SQUAMOUS CELL CARCINOMA 0/52 0/52 4/52
|
Neoplastic Lesions
|
Yes
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 2/52 3/52
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULE 1/52 6/52 7/52
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 8/50
|
Neoplastic Lesions
|
No
|
TR-269
|
542-75-6 |
1,3-Dichloropropene (Telone II) |
Mice |
B6C3F1 |
Female |
Gavage |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL CARCINOMA 0/50 8/50 21/48
|
Neoplastic Lesions
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Rats |
F344/N |
Female |
Inhalation |
Adrenal Gland Medulla
|
Equivocal Evidence |
Equivocal Evidence |
BENIGN OR MALIGNANT PHEOCHROMOCYTOMA 3/50 4/50 1/49 8/49
|
May Have Been Related
|
Yes
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/50 2/49 2/49
|
May Have Been Related
|
Yes
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 2/50 5/50 COMBINED 0/50 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Male |
Inhalation |
Liver
|
Some Evidence |
Equivocal Evidence |
HEPATOCELLULAR CARCINOMA 10/50 11/50 16/49 21/49
|
May Have Been Related
|
No
|
TR-484
|
111-76-2 |
2-Butoxyethanol (ethylene glycol monobutyl ether) |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Liver)
|
Some Evidence |
Some Evidence |
HEMANGIOSARCOMA 0/50 1/50 2/49 4/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/51 1/53 10/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 1/51 5/55 0/60
|
Neoplastic Lesions
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/52 1/50 5/51 3/50
|
May Have Been Related
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/51 2/50 2/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/51 1/50 2/49 COMBINED 0/50 3/51 3/50 4/49
|
May Have Been Related
|
Yes
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 0/53 0/51 1/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/52 6/50 8/51 15/50 OR CARCINOMA 1/52 6/50 5/51 7/50 COMBINED 3/52 12/50 13/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 6/51 12/50 18/49 OR CARCINOMA 1/50 1/51 4/50 4/49 COMBINED 4/50 7/51 16/50 22/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 27/51 29/53 40/51 34/55 25/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 3/51 4/55 11/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Clear Evidence |
ADENOMA OR CARCINOMA 0/51 0/53 0/51 2/53 5/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/51 0/53 1/51 3/55 1/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 3/50 2/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 3/52 3/50 9/51 17/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 2/52 2/50 6/51 5/50 COMBINED 5/52 5/50 15/51 19/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 12/50 4/51 12/50 21/49 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 3/50 7/51 8/50 11/49 COMBINED 15/50 11/51 16/50 25/49
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/51 0/53 3/51 1/55 4/60 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 1/53 0/51 3/55 3/60 COMBINED 1/51 1/53 3/51 4/55 7/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/52 0/50 1/51 2/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 25/50 45/51 46/53 45/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 0/51 4/53 6/51 6/55 5/60 OR ADENOMA 0/51 0/53 1/51 1/55 0/60 COMBINED 0/51 4/53 7/51 7/55 5/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 0/51 3/53 8/51 9/55 26/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/51 4/53 5/52 OR SQUAMOUS CELL CARCINOMA 0/50 1/51 1/53 1/52 COMBINED 2/50 3/51 5/53 6/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/51 4/53 8/51 10/55 12/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 1/51 0/55 2/60 COMBINED 0/51 4/53 9/51 10/55 13/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Pancreas Acinar Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 1/51 2/53 4/51 3/53 3/59
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Seminal Vesicle
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 0/51 0/55 1/59 OR CARCINOMA 0/51 0/53 0/51 0/55 1/59 COMBINED 0/51 0/53 0/51 0/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/51 0/53 2/51 5/55 11/60 OR KERATOACANTHOMA 3/51 5/53 11/51 16/55 10/60 OR TRICHOEPITHELIOMA 0/51 0/53 0/51 1/55 1/60 OR BASAL CELL ADENOMA 0/51 1/53 0/51 3/55 6/60 OR BASAL CELL CARCINOMA 0/51 0/53 2/51 2/55 0/60 OR SQUAMOUS CELL CARCINOMA 0/51 0/53 0/51 0/55 1/60 COMBINED 4/51 6/53 14/51 24/55 21/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/52 1/50 4/51 11/50
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
FIBROMA 2/51 8/53 11/51 15/55 7/60 OR FIBROSARCOMA 0/51 1/53 0/51 0/55 1/60 OR SARCOMA 0/51 0/53 2/51 3/55 2/60 COMBINED 2/51 9/53 13/51 16/55 10/60
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Female |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/51 2/53 3/52 OR CARCINOMA 0/50 0/51 0/53 1/52 COMBINED 0/50 0/51 2/53 4/52
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 1/53 2/51 2/55 7/59 OR CARCINOMA 0/51 1/53 4/51 1/55 2/59 COMBINED 0/51 2/53 6/51 3/55 9/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
TRANSITIONAL CELL PAPILLOMA 0/51 0/53 1/51 2/55 1/59 OR TRANSITIONAL CELL CARCINOMA 0/51 0/53 0/51 1/55 1/59 COMBINED 0/51 0/53 1/51 3/55 2/59
|
Neoplastic Lesions
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Clear Evidence |
Equivocal Evidence |
HEMANGIOMA AND HEMANGIOSARCOMA 1/52 2/50 0/51 5/50
|
May Have Been Related
|
No
|
TR-452
|
3296-90-0 |
2,2-bis(Bromomethyl)-1,3-propanediol |
Rats |
F344/N |
Male |
Dosed-Feed |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/51 0/53 1/51 3/55 2/60 OR CARCINOMA 2/51 1/53 3/51 2/55 15/60 COMBINED 2/51 1/53 4/51 5/55 15/60
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 3/50 OR ADENOCARCINOMA 0/50 0/50 3/50 COMBINED 0/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 9/50 38/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 19/50 33/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/49 17/50 OR SQUAMOUS CELL CARCINOMA 0/50 7/47 6/50 COMBINED 0/50 18/49 19/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 12/50 20/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/49 COMBINED 0/50 14/50 21/49
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 23/50
|
Neoplastic Lesions
|
Yes
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 17/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/50 4/49; ADENOMATOUS POLYP 0/50 12/50 37/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 8/50 11/50; ADENOMATOUS POLYP 1/50 13/50 29/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 2/50 9/50 OR CARCINOMA 0/50 0/50 3/50 COMBINED 1/50 2/50 11/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/50 10/50 11/50 OR CARCINOMA 0/50 2/50 6/50 COMBINED 0/50 11/50 14/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Liver
|
Clear Evidence |
Clear Evidence |
NEOPLASTIC NODULES 0/49 3/50 2/50 OR CARCINOMA 0/49 1/50 3/50 COMBINED 0/49 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 3/50 4/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 0/50 0/50 COMBINED 1/50 3/50 4/50
|
May Have Been Related
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 1/50 6/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 44/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 48/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 27/50 41/50 OR SQUAMOUS CELL CARCINOMA 0/50 15/50 27/50 COMBINED 0/50 39/50 49/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 40/50 33/50 OR SQUAMOUS CELL CARCINOMA 0/50 16/50 25/50 COMBINED 0/50 47/50 48/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 1/50 6/50; SEBACEOUS GLAND ADENOMA 0/50 3/50 2/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Mice |
B6C3F1 |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 0/50 3/50 11/50; SEBACEOUS GLAND ADENOMA 0/50 1/50 8/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 3/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA OR KERATOACANTHOMA 0/50 3/50 18/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 0/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 8/50 COMBINED 1/50 8/50 8/50; BASAL CELL NEOPLASMS, SEBACEOUS GLAND ADENOMA, OR KERATOACANTHOMA 0/50 20/50 31/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Vascular System (Spleen)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 3/50 OR HEMANGIOSARCOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Female |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 7/50 3/50 OR ADENOCARCINOMA 1/50 2/50 19/50 COMBINED 1/50 9/50 22/50
|
Neoplastic Lesions
|
No
|
TR-400
|
96-13-9 |
2,3-Dibromo-1-propanol |
Rats |
F344/N |
Male |
Topical Application |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 7/50 OR ADENOCARCINOMA 0/50 8/50 29/50 COMBINED 0/50 9/50 35/50
|
Neoplastic Lesions
|
Yes
|
TR-509
|
142-83-6 |
2,4-Hexadienal |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 2/49 11/50 13/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/49 0/50 7/50 COMBINED 2/50 2/49 11/50 18/50
|
Neoplastic Lesions
|
Yes
|
TR-509
|
142-83-6 |
2,4-Hexadienal |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 4/50 5/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 0/50 2/50 COMBINED 2/50 4/50 5/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-509
|
142-83-6 |
2,4-Hexadienal |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 17/50
|
Neoplastic Lesions
|
Yes
|
TR-509
|
142-83-6 |
2,4-Hexadienal |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 10/50 29/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 3/50 11/50 29/50
|
Neoplastic Lesions
|
No
|
TR-509
|
142-83-6 |
2,4-Hexadienal |
Mice |
B6C3F1 |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Equivocal Evidence |
(TONGUE) SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 2/50
|
May Have Been Related
|
Yes
|
TR-300
|
563-47-3 |
3-Chloro-2-methylpropene |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 15/48 29/44; SQUAMOUS CELL CARCINOMA 0/50 1/48 2/44
|
Neoplastic Lesions
|
Yes
|
TR-300
|
563-47-3 |
3-Chloro-2-methylpropene |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/49 19/49 30/49; SQUAMOUS CELL CARCINOMA 0/49 5/49 7/49
|
Neoplastic Lesions
|
Yes
|
TR-300
|
563-47-3 |
3-Chloro-2-methylpropene |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-300
|
563-47-3 |
3-Chloro-2-methylpropene |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 5/50 30/48; SQUAMOUS CELL CARCINOMA 0/50 0/50 2/48
|
Neoplastic Lesions
|
No
|
TR-095
|
6959-48-4 |
3-Chloromethylpyridine hydrochloride |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Equivocal Evidence |
Equivocal |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-095
|
6959-48-4 |
3-Chloromethylpyridine hydrochloride |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-095
|
6959-48-4 |
3-Chloromethylpyridine hydrochloride |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-095
|
6959-48-4 |
3-Chloromethylpyridine hydrochloride |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Adrenal Gland Cortex
|
Clear Evidence |
Equivocal Evidence |
Adenoma 1/50 1/50 3/50 4/49
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Malignant Lymphoma: 2/50 5/50 8/50 7/50
|
May Have Been Related
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell carcinoma 0/50 1/50 1/49 3/50
|
Neoplastic Lesions
|
Yes
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 1/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 1/50 1/50 1/49 3/49
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
Cholangiocarcinoma 0/50 4/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma or carcinoma 0/49 2/50 1/50 4/50 alveolar/bronchiolar adenoma or carcinoma 3/49 8/50 5/50 10/50 cystic keratinizing epithelioma 0/49 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/bronchiolar adenoma 5/50 16/50 12/49 6/50 alveolar/bronchiolar adenoma or carcinoma 7/50 17/50 15/49 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 6/50 26/49 39/49
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
Cystic keratinizing epithelioma 0/50 14/50 31/50 37/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 0/50 0/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Mucosa: Gingival squamous cell carcinoma 1/50 5/50 4/50 5/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
Fibrosarcoma 1/50 6/50 5/50 8/50 fibrosarcoma or malignant schwannoma 2/50 8/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thoracic Cavity
|
Clear Evidence |
Equivocal Evidence |
Malignant Schwannoma: 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Rats |
Harlan Sprague-Dawley |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/50 3/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/0 0/1 0/0 1/2
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Ureter
|
Clear Evidence |
Equivocal Evidence |
Transitional epithelial carcinoma: 0/43 0/45 1/47 0/50
|
May Have Been Related
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Female |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-558
|
14047-09-7 |
3,3',4,4'-Tetrachloroazobenzene |
Mice |
B6C3F1/N |
Male |
Gavage |
Urinary System
|
Clear Evidence |
Clear Evidence |
Urethra: Transitional epithelial gland carcinoma 0/50 32/50 46/49 49/50
|
Neoplastic Lesions
|
Yes
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-063
|
95-83-0 |
4-Chloro-o-phenylenediamine |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Positive |
Positive |
(TRANSITIONAL CELL PAPILLOMA, TRANSITIONAL CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 1/4 6/48 12/47 3/48 8/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 2/48 2/48 1/48 5/48 8/48
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 4/46 0/46 2/48 5/45 8/42
|
Neoplastic Lesions
|
Yes
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/46 2/45 2/46 6/47 6/44 squamous cell carcinoma 0/46 0/45 0/46 1/47 2/44 squamous cell papilloma or carcinoma 0/46 2/45 2/46 7/47 8/44
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 0/45 8/44 20/48 32/47 31/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/46 13/46 27/47 36/47 39/47 adenocarcinoma 0/46 0/46 0/47 1/47 1/47 adenoma or adenocarcinoma 2/46 13/46 27/47 37/47 39/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 2/48 1/48 0/48 2/48 4/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant Schwannoma 1/48 2/48 3/48 4/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 1/48 3/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 1/47 4/47 6/48 11/45 19/45
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 5/47 6/46 13/47 10/45 19/48 alveolar/bronchiolar adenoma or carcinoma 6/47 6/46 14/47 10/45 20/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/47 1/46 1/48 2/45 4/42 adenocarcinoma 0/47 4/46 6/48 2/45 13/42 adenoacanthoma or adenocarcinoma 0/47 4/46 7/48 4/45 17/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 18/48 24/46 22/47 31/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma or carcinoma 0/48 2/48 1/48 3/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
benign granulose cell tumor 0/46 1/45 0/48 1/45 5/42
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Pancreas Islet Cell
|
Clear Evidence |
Clear Evidence |
adenoma 1/46 2/48 4/48 1/48 6/48 carcinoma 0/46 0/48 0/48 1/48 0/48 adenoma or carcinoma 1/46 2/48 4/48 2/48 6/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma, fibrous histocytoma, myxosarcoma, neurofibrosarcoma, or sarcoma 0/48 0/46 3/48 10/45 6/43 squamous cell carcinoma 0/48 0/46 0/48 0/45 2/43
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
subcutaneous tissue fibroma, fibrosarcoma or sarcoma 1/48 0/48 0/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 1/48 2/48 1/48 1/48 5/48
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 0/48 1/48 0/48 2/47 carcinoma 0/48 0/48 1/48 3/48 2/47 adenoma or carcinoma 0/48 0/48 2/48 3/48 4/47
|
Neoplastic Lesions
|
No
|
TR-575
|
79-06-1 |
Acrylamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/47 1/48 1/47 1/48 3/48 carcinoma 1/47 2/48 3/47 6/48 6/48 l adenoma or carcinoma 1/47 3/48 4/47 6/48 9/48
|
Neoplastic Lesions
|
Yes
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/50 6/50 24/50 19/50 SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 11/50 COMBINED 3/50 7/50 25/50 29/50
|
Neoplastic Lesions
|
Yes
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 3/50 4/50 19/50 25/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 8/50 9/50 COMBINED 3/50 4/50 26/50 32/50
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 10/50 10/50 25/50 23/50 ADENOMA OR CARCINOMA 11/50 10/50 26/50 25/50
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 16/50 24/50 27/50 ADENOMA OR CARCINOMA 6/50 16/50 27/50 30/50
|
Neoplastic Lesions
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA 6/50 6/50 14/50 9/50
|
May Have Been Related
|
No
|
TR-506
|
107-13-1 |
Acrylonitrile |
Mice |
B6C3F1 |
Female |
Gavage |
Ovary
|
Clear Evidence |
Equivocal Evidence |
BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/50 0/50 4/50 1/50
|
May Have Been Related
|
No
|
TR-378
|
100-52-7 |
Benzaldehyde |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-378
|
100-52-7 |
Benzaldehyde |
Rats |
F344/N |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-378
|
100-52-7 |
Benzaldehyde |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-378
|
100-52-7 |
Benzaldehyde |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 2/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 5/50 OR SQUAMOUS CELL CARCINOMA 0/50 1/50 1/50 COMBINED 2/50 9/50 5/50
|
Neoplastic Lesions
|
Yes
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 2/49 7/39 10/48 OR SQUAMOUS CELL CARCINOMA 0/49 4/39 3/48 COMBINED 2/49 11/39 13/48
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOCARCINOMA 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 22/48 21/47; HEPATOBLASTOMA 0/50 1/48 2/47; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 3/50 3/48 1/47 COMBINED 4/50 25/48 22/47
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/49 24/39 34/48; HEPATOBLASTOMA 0/49 3/39 18/48; ADENOMA, HEPATOBLASTOMA, OR CARCINOMA 9/49 8/39 9/48 COMBINED 12/49 31/39 40/48
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 5/48 13/47 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 4/48 3/47 COMBINED 2/50 9/48 14/47
|
Neoplastic Lesions
|
No
|
TR-370
|
271-89-6 |
Benzofuran |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/49 7/39 15/48 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/49 3/39 5/48 COMBINED 10/49 9/39 19/48
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/48
|
Neoplastic Lesions
|
Yes
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 3/49 3/48 9/49 OR SQUAMOUS CELL CARCINOMA 1/49 1/48 2/49 COMBINED 4/49 4/48 11/49
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 0/50 6/50
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 0/50 5/49 13/50
|
Neoplastic Lesions
|
No
|
TR-250
|
140-11-4 |
Benzyl acetate |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 22/50 27/50 37/49
|
Neoplastic Lesions
|
Yes
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/49 1/49 OR SQUAMOUS CELL CARCINOMA 0/50 0/49 1/49 COMBINED 0/50 0/49 2/49
|
May Have Been Related
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Positive |
Positive |
CARCINOMA 5/50 13/50 17/50
|
Neoplastic Lesions
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 1/50 4/50 8/50
|
Neoplastic Lesions
|
No
|
TR-239
|
108-60-1 |
bis(2-Chloro-1-methylethyl) ether |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
ALVEOLAR/BRONCHIOLAR ADENOMA 5/50 13/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 0/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Intestines (Small)
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 1/50 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 2/50 1/50 1/50 OR CARCINOMA 0/50 1/50 0/50 0/50 COMBINED 0/50 3/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/49 12/50 17/49 41/49; CARCINOMA 5/49 5/50 6/49 12/49
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 16/50 19/50 17/50 40/50; CARCINOMA 7/50 3/50 8/50 17/50
|
Neoplastic Lesions
|
No
|
TR-430
|
28407-37-6 |
C.I. Direct Blue 218 |
Rats |
F344/N |
Male |
Dosed-Feed |
Oral Cavity
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 0/50 5/51; SQUAMOUS CELL CARCINOMA 0/50 0/50 0/50 1/51; BASOSQUAMOUS TUMOR BENIGN 0/50 0/50 0/50 1/51
|
Neoplastic Lesions
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/49 1/50 0/50; FIBROSARCOMA 0/49 1/50 0/50; SARCOMA 0/49 0/50 1/50
|
May Have Been Related
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Glandular Stomach
|
Positive |
Equivocal Evidence |
ADENOMA 0/49 1/50 0/50; ADENOCARCINOMA 0/49 1/501/50; SARCOMA 0/49 0/50 1/50
|
May Have Been Related
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Hematopoietic System
|
Positive |
Equivocal Evidence |
LYMPHOMA 10/50 16/50 19/50
|
May Have Been Related
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
ADENOMA 0/50 6/50 12/50
|
Neoplastic Lesions
|
No
|
TR-222
|
2832-40-8 |
C.I. Disperse Yellow 3 |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
NEOPLASTIC NODULE 1/49 15/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous Cell Papilloma 0/50 0/50 0/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 2/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 3/50 3/50 8/50 OR CARCINOMA 1/50 2/50 0/50 1/50 COMBINED 2/50 5/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 2/50 5/50 8/50 10/50 OR CARCINOMA 0/50 0/50 2/50 2/50 COMBINED 2/50 5/50 10/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/49 1/50 3/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/50 2/49 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/49 0/50 0/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 0/49 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
(SINGLE SECTIONS) ADENOMA 0/50 1/50 1/50 2/50 (SINGLE AND STEP SECTIONS) ADENOMA 1/50 7/50 6/50 7/50 OR CARCINOMA 0/50 2/50 0/50 1/50 COMBINED 1/50 9/50 6/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 17/50 19/49 11/50 16/50 OR CARCINOMA 4/50 11/49 14/50 19/50 COMBINED 20/50 26/49 20/50 30/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Lung
|
Clear Evidence |
Equivocal Evidence |
Alveolar/Bronchiolar Adenoma 1/49 0/50 0/50 3/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 16/49 29/50 26/50 or Alveolar/Bronchiolar Carcinoma 2/50 14/49 16/50 28/50 Combined 4/50 28/49 34/50 42/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 8/50 18/50 22/50 28/50 or Alveolar/Bronchiolar Carcinoma 6/50 12/50 23/50 28/50 Combined 13/50 28/50 36/50 43/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Lung
|
Clear Evidence |
Clear Evidence |
Alveolar/Bronchiolar Adenoma 2/50 0/50 3/49 3/50 or Alveolar/Bronchiolar Carcinoma 0/50 2/50 1/49 4/50 Combined 2/50 2/50 4/49 6/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 3/50 4/50 7/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 24/49 32/50 36/50 36/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 4/50 8/50 3/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 2/50 7/50 OR SQUAMOUS CELL CARCINOMA 0/49 1/50 3/50 4/50 COMBINED 1/49 3/50 5/50 11/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 4/50 10/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 2/50 COMBINED 0/50 2/50 5/50 12/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 11/50 11/50 18/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/49 1/50 0/50 3/50 OR CARCINOMA 0/49 0/50 1/50 2/50 COMBINED 1/49 1/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/49 4/50 OR CARCINOMA 0/50 0/50 2/49 1/50 COMBINED 0/50 2/50 4/49 5/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Female |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM CARCINOMA 0/49 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Rats |
F344/N |
Male |
Inhalation |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
TRANSITIONAL EPITHELIUM PAPILLOMA 0/50 0/50 0/50 1/49 OR CARCINOMA 0/50 0/50 1/50 0/49
|
May Have Been Related
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 0/50 2/50 3/50 OR HEMANGIOSARCOMA 4/50 6/50 17/50 5/50 COMBINED 4/50 6/50 18/50 8/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Male |
Inhalation |
Vascular System (Unspecified)
|
Clear Evidence |
Clear Evidence |
HEMANGIOMA 0/50 1/50 2/50 2/50 OR HEMANGIOSARCOMA 3/50 13/50 22/50 19/50 COMBINED 3/50 14/50 23/50 21/50
|
Neoplastic Lesions
|
No
|
TR-467
|
126-99-8 |
Chloroprene |
Mice |
B6C3F1 |
Female |
Inhalation |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 0/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/52 5/50 2/51 2/51
|
May Have Been Related
|
Yes
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 2/50 8/50 2/50 0/51
|
May Have Been Related
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Female |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/49 0/50 0/50 2/49, STEP SECTIONS 0/49 0/50 1/50 1/49
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Some Evidence |
Some Evidence |
ADENOMA 1/49 2/50 2/51 1/50, STEP SECTIONS 0/49 4/50 5/51 4/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 8/50 26/49 29/51 12/50
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 2/51 5/49 7/49 20/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 0/51 0/49 0/49 7/51 COMBINED 2/51 5/49 7/49 27/51
|
Neoplastic Lesions
|
No
|
TR-422
|
91-64-5 |
Coumarin |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Some Evidence |
Some Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 14/50 8/50 14/50 24/51 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 1/50 1/50 2/50 1/51 COMBINED 14/50 9/50 15/50 25/51
|
Neoplastic Lesions
|
Yes
|
TR-550
|
1319-77-3 |
Cresols |
Mice |
B6C3F1/N |
Female |
Dosed-Feed |
Forestomach
|
Some Evidence |
Some Evidence |
squamous cell papilloma (0/50 1/50 1/49 10/50)
|
Neoplastic Lesions
|
No
|
TR-550
|
1319-77-3 |
Cresols |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
Renal tubule adenoma (standard evaluation - 0/50 0/50 0/50 3/50; standard and extended evaluations combined - 0/50 0/50 0/50 4/50)
|
May Have Been Related
|
Yes
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Harderian Gland
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Male |
Dosed-Feed |
Liver
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOMA OR HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Male |
Dosed-Feed |
Vascular System (Unspecified)
|
Positive |
Positive |
HEMANGIOSARCOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
No
|
TR-100
|
135-20-6 |
Cupferron |
Rats |
F344/N |
Female |
Dosed-Feed |
Zymbal Gland
|
Positive |
Positive |
CARCINOMA
|
Neoplastic Lesions
|
Yes
|
TR-342
|
62-73-7 |
Dichlorvos |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 5/49 6/49 18/50
|
Neoplastic Lesions
|
Yes
|
TR-342
|
62-73-7 |
Dichlorvos |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 1/50 5/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 11/50 20/50 21/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Equivocal Evidence |
Equivocal Evidence |
FIBROADENOMA 9/50 19/50 16/50 OR ADENOMA 0/50 0/50 1/50 COMBINED 9/50 19/50 17/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Female |
Gavage |
Pancreas Acinar Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 2/50 3/47 6/50
|
Neoplastic Lesions
|
No
|
TR-342
|
62-73-7 |
Dichlorvos |
Rats |
F344/N |
Male |
Gavage |
Pancreas Acinar Cell
|
Some Evidence |
Some Evidence |
ADENOMA 25/50 30/49 33/50
|
Neoplastic Lesions
|
Yes
|
TR-257
|
101-90-6 |
Diglycidyl resorcinol ether (DGRE) |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/47 5/49 10/49; SQUAMOUS CELL CARCINOMA 0/47 12/49 23/49
|
Neoplastic Lesions
|
Yes
|
TR-257
|
101-90-6 |
Diglycidyl resorcinol ether (DGRE) |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/47 4/49 10/50; SQUAMOUS CELL CARCINOMA 0/47 14/49 25/50
|
Neoplastic Lesions
|
Yes
|
TR-257
|
101-90-6 |
Diglycidyl resorcinol ether (DGRE) |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/49 7/50 1/50; SQUAMOUS CELL CARCINOMA 0/49 34/50 3/50
|
Neoplastic Lesions
|
Yes
|
TR-257
|
101-90-6 |
Diglycidyl resorcinol ether (DGRE) |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/50 17/50 6/49; SQUAMOUS CELL CARCINOMA 0/50 38/50 4/49
|
Neoplastic Lesions
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 3/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50
|
Neoplastic Lesions
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Equivocal Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/48; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/48
|
Neoplastic Lesions
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 0/50 0/50 5/50; ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/50 20/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-287
|
868-85-9 |
Dimethyl hydrogen phosphite |
Rats |
F344/N |
Female |
Gavage |
Lung
|
Equivocal Evidence |
Equivocal Evidence |
ALVEOLAR/BRONCHIOLAR CARCINOMA 0/50 1/49 3/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/49 3/50 1/49
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Esophagus
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 3/49 OR SQUAMOUS CELL CARCINOMA 0/50 4/50 1/49 COMBINED 0/50 6/50 4/49
|
Neoplastic Lesions
|
Yes
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 0/50 40/47 36/43
|
Neoplastic Lesions
|
Yes
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/48 3/47 8/44; SQUAMOUS CELL CARCINOMA 0/48 42/47 35/44
|
Neoplastic Lesions
|
Yes
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 4/50 1/49 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 1/49 COMBINED 1/50 9/50 2/49
|
Neoplastic Lesions
|
Yes
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/49 7/50 0/50; SQUAMOUS CELL CARCINOMA 0/49 7/50 0/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/50 3/49 6/41; CARCINOMA 0/50 11/49 28/41; SQUAMOUS CELL CARCINOMA 0/50 2/49 2/41
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
ADENOCARCINOMA 0/47 8/46 4/32; CARCINOMA 0/47 12/46 24/32; SQUAMOUS CELL CARCINOMA 0/47 3/46 0/32
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50 OR SQUAMOUS CELL CARCINOMA 0/50 2/50 1/50 COMBINED 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Rats |
F344/N |
Male |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 2/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 2/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-316
|
513-37-1 |
Dimethylvinyl chloride (DMVC) |
Mice |
B6C3F1 |
Male |
Gavage |
Preputial Gland
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL CARCINOMA 1/48 3/47 16/44
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Rats |
Sprague Dawley |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Rats |
Sprague Dawley |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Heart
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Heart
|
Positive |
Positive |
(SARCOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Hematopoietic System
|
Positive |
Positive |
(LYMPHOMA OR LEUKEMIA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Female |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-059
|
22966-79-6 |
Estradiol mustard |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Female |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
No
|
TR-510
|
64-17-5 |
Ethanol |
Mice |
MV |
Male |
Dosed-Water |
Unspecified
|
Inadequate Study |
|
Not applicable
|
Not applicable
|
Yes
|
TR-259
|
140-88-5 |
Ethyl acrylate |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 1/50 4/49 5/48 OR SQUAMOUS CELL CARCINOMA 0/50 1/49 2/48 COMBINED 1/50 5/49 7/48
|
Neoplastic Lesions
|
Yes
|
TR-259
|
140-88-5 |
Ethyl acrylate |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 0/48 4/47 9/50 OR SQUAMOUS CELL CARCINOMA 0/48 2/47 5/50 COMBINED 0/48 5/47 12/50
|
Neoplastic Lesions
|
Yes
|
TR-259
|
140-88-5 |
Ethyl acrylate |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 1/50 6/50 9/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 2/50 COMBINED 1/50 6/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-259
|
140-88-5 |
Ethyl acrylate |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
SQUAMOUS CELL PAPILLOMA 1/50 15/50 29/50 OR SQUAMOUS CELL CARCINOMA 0/50 5/50 12/50 COMBINED 1/50 18/50 36/50
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Rats |
F344/N |
Female |
Gavage |
Unspecified
|
No Evidence |
|
Not applicable
|
Not applicable
|
Yes
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 0/50 1/50 6/50
|
May Have Been Related
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 1/49 1/50 OR CARCINOMA 0/50 1/50 0/49 0/50 COMBINED 0/50 1/50 1/49 1/50
|
May Have Been Related
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 9/50 13/50 11/49 19/50; CARCINOMA 7/50 12/50 6/49 21/50
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 1/50 3/50 5/50 8/50
|
Neoplastic Lesions
|
No
|
TR-382
|
98-01-1 |
Furfural |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Some Evidence |
Some Evidence |
CHOLANGIOCARCINOMA 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
All Organs
|
Clear Evidence |
Equivocal Evidence |
Mononuclear Cell Leukemia 21/48 26/48 27/48 27/47 31/48
|
May Have Been Related
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
All Organs
|
Clear Evidence |
Clear Evidence |
Mononuclear Cell Leukemia 14/48 11/48 21/48 19/48 27/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
carcinoma 4/48 6/48 7/48 11/48 14/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/45 3/48 10/47 17/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Epididymis or Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/48 3/48 10/47 17/48
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/45 1/45 1/47 5/45 9/44
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/47 2/45 3/48 2/45 10/41 squamous cell carcinoma 0/47 0/45 0/48 0/45 2/41 squamous cell papilloma or carcinoma 0/47 2/45 3/48 2/45 12/41
|
Neoplastic Lesions
|
Yes
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/48 1/48 0/48 0/47 3/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 2/45 19/47 20/47 24/46 40/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
adenoma 3/47 17/47 23/47 32/46 42/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
malignant schwannoma 2/48 3/48 3/48 7/47 8/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 3/46 5/48 3/47 7/47 9/44
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 0/47 7/46 7/47 13/47 17/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
adenoacanthoma 0/45 0/48 0/47 1/47 8/45 adenocarcinoma 1/45 1/48 2/47 9/47 11/45 adenoacanthoma or adenocarcinoma 1/45 1/48 2/47 9/47 18/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
fibroadenoma 16/48 26/48 35/48 33/48 36/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Tongue: squamous cell papilloma 0/48 1/48 0/48 1/48 0/48 squamous cell carcinoma 0/48 0/48 0/48 0/48 1/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa: squamous cell papilloma 1/48 1/48 2/48 0/48 4/48 squamous cell carcinoma 0/48 0/48 0/48 1/48 2/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa or tongue: squamous cell papilloma or carcinoma 1/48 2/48 2/48 2/48 7/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa or tongue: squamous cell papilloma or carcinoma 2/48 2/48 2/48 3/47 7/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Oral mucosa: squamous cell papilloma 1/48 1/48 0/48 2/47 3/48 squamous cell carcinoma 1/48 0/48 1/48 1/47 0/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Tongue: squamous cell papilloma 0/48 1/48 0/48 1/47 4/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Equivocal Evidence |
granulosa cell tumor – benign or malignant 0/45 0/47 0/47 3/46 3/44
|
May Have Been Related
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
fibrosarcoma 0/45 1/48 2/47 2/47 9/45 sarcoma 0/45 0/48 1/47 3/47 3/45 fibrosarcoma or sarcoma 0/45 1/48 3/47 5/47 12/45
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 0/47 1/48 2/47 1/47 8/46 squamous cell carcinoma 0/47 0/48 0/47 0/47 2/46 squamous cell papilloma or carcinoma 0/47 1/48 2/47 1/47 9/46
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Testis
|
Clear Evidence |
Clear Evidence |
malignant mesothelioma 0/48 1/47 3/48 6/47 13/48
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Female |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 0/48 3/48 3/46 1/46 5/47 follicular cell carcinoma 0/48 0/48 2/46 3/46 3/47 follicular cell adenoma or carcinoma 0/48 3/48 5/46 4/46 8/47
|
Neoplastic Lesions
|
No
|
TR-588
|
5694-00-8 |
Glycidamide |
Rats |
F344 (NCTR) |
Male |
Dosed-Water |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
adenoma 2/47 1/42 3/48 3/47 8/46 follicular cell carcinoma 0/47 2/42 3/48 1/47 5/46 follicular cell adenoma or carcinoma 2/47 3/42 6/48 4/47 13/46
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 4/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Brain
|
Clear Evidence |
Clear Evidence |
GLIOMA 0/50 5/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Clitoral Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Epididymis
|
Clear Evidence |
Equivocal Evidence |
SARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
|
Neoplastic Lesions
|
Yes
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Equivocal Evidence |
FIBROSARCOMA 0/50 0/50 2/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
LEUKEMIA 13/50 14/50 20/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 3/50 8/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 3/50 34/50 39/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Subcutaneous Tissue
|
Clear Evidence |
Clear Evidence |
SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Female |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Male |
Gavage |
Urinary Bladder
|
Clear Evidence |
Equivocal Evidence |
CARCINOMA 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Mice |
B6C3F1 |
Female |
Gavage |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
|
Neoplastic Lesions
|
No
|
TR-374
|
556-52-5 |
Glycidol |
Rats |
F344/N |
Male |
Gavage |
Zymbal Gland
|
Clear Evidence |
Clear Evidence |
CARCINOMA 1/50 3/50 6/50
|
Neoplastic Lesions
|
Yes
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Forestomach
|
Some Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 1/49 2/50 5/49
|
May Have Been Related
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Harderian Gland
|
Some Evidence |
Some Evidence |
ADENOMA 6/50 8/40 13/50 OR CARCINOMA 0/50 0/40 1/50 COMBINED 6/50 8/40 14/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Hematopoietic System
|
Some Evidence |
Some Evidence |
LEUKEMIA 14/50 29/50 24/50
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Some Evidence |
Equivocal Evidence |
ADENOMA 0/48 0/47 2/49
|
May Have Been Related
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Mice |
B6C3F1 |
Female |
Gavage |
Pituitary Gland
|
Some Evidence |
Some Evidence |
ADENOMA 10/47 15/45 24/46
|
Neoplastic Lesions
|
No
|
TR-340
|
5634-39-9 |
Iodinated glycerol |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Some Evidence |
CARCINOMA 0/49 5/49 1/49
|
Neoplastic Lesions
|
No
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Equivocal Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 0/49 2/50
|
Neoplastic Lesions
|
Yes
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Some Evidence |
Some Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 3/50 12/50
|
Neoplastic Lesions
|
No
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Mice |
B6C3F1 |
Male |
Gavage |
Kidney Tubular Cell
|
Equivocal Evidence |
Equivocal Evidence |
ADENOMA 0/50 0/50 2/49 OR ADENOCARCINOMA 0/50 0/50 1/49
|
Neoplastic Lesions
|
No
|
TR-408
|
7487-94-7 |
Mercuric chloride |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Some Evidence |
Equivocal Evidence |
ADENOMA 1/50 4/50 0/50 OR CARCINOMA 1/50 2/50 6/50
|
May Have Been Related
|
Yes
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA OR CARCINOMA 0/50 0/50 1/50 3/50
|
May Have Been Related
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Male |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
MALIGNANT NEUROENDOCRINE TUMOR 0/49 0/48 0/49 2/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
BENIGN NEUROENDOCRINE TUMOR 0/50 0/50 13/50 9/50 5/50 OR MALIGNANT NEUROENDOCRINE TUMOR 0/50 1/50 12/50 26/50 36/50 COMBINED 0/50 1/50 25/50 34/50 41/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
BENIGN NEUROENDOCRINE TUMOR 1/50 0/50 0/50 3/50 2/50 OR MALIGNANT NEURENDOCRINE TUMOR 0/50 0/50 0/50 4/50 2/50 COMBINED 1/50 0/50 0/50 7/50 4/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Kidney Tubular Cell
|
Clear Evidence |
Clear Evidence |
ADENOMA (STANDARD AND EXTENDED COMBINED) 4/50 6/50 17/50 13/50 20/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 20/50 48/50 46/49 41/50 OR CARCINOMA 7/50 37/50 47/49 47/50 COMBINED 25/50 50/50 49/49 49/50; HEPATOBLASTOMA 0/50 6/50 11/49 15/50; HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Mice |
B6C3F1 |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 26/49 43/50 38/50 39/50 CARCINOMA 10/49 20/50 19/50 9/50 COMBINED 31/49 47/50 46/50 40/50; HEPATOBLASTOMA 0/49 0/50 1/50 3/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 1/50 8/50 11/49 33/49 43/50 OR CARCINOMA 0/50 0/50 4/49 8/49 22/50 COMBINED 1/50 8/50 14/49 34/49 43/50; HEPATOCHOLANGIOMA 0/50 0/50 0/49 0/49 8/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 0/49 3/49 9/50 COMBINED 0/50 0/50 0/49 3/49 17/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 5/50 12/50 23/50 38/50 32/50 OR CARCINOMA 2/50 3/50 14/50 25/50 36/50 COMBINED 7/50 14/50 28/50 43/50 45/50; HEPATOCHOLANGIOMA 0/50 0/50 0/50 1/50 6/50 OR HEPATOCHOLANGIOCARCINOMA 0/50 0/50 1/50 1/50 7/50 COMBINED 0/50 0/50 1/50 2/50 13/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
FIBROADENOMA 5/50 5/50 15/50 13/50 6/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Mesothelium (Abdominal Cavity/Tunica Vaginalis)
|
Clear Evidence |
Clear Evidence |
MESOTHELIOMA 1/50 3/50 5/50 12/50 5/50
|
Neoplastic Lesions
|
No
|
TR-491
|
93-15-2 |
Methyleugenol |
Rats |
F344/N |
Male |
Gavage |
Skin
|
Clear Evidence |
Clear Evidence |
FIBROMA 1/50 9/50 8/50 5/50 4/50 OR FIBROMA OR FIBROSARCOMA 1/50 12/50 8/50 8/50 4/50
|
Neoplastic Lesions
|
Yes
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Forestomach
|
Clear Evidence |
Clear Evidence |
squamous cell papilloma 1/50, 5/50, 6/50, 7/50; squamous cell papilloma or carcinoma 1/50, 6/50, 6/50, 7/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma 17/50, 19/50, 37/50, 44/50; hepatocellular carcinoma 6/50, 13/50, 18/50, 31/50; hepatoblastoma 0/50, 1/50, 0/50, 4/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular adenoma, multiple 17/50, 19/50, 27/50, 26/50; hepatocellular carcinoma 22/50, 25/50, 30/50, 36/50; hepatoblastoma 1/50, 5/50, 10/50, 8/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 0/50, 4/49; hepatocellular adenoma or carcinoma 0/50, 1/50, 1/50, 7/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Liver
|
Clear Evidence |
Clear Evidence |
hepatocellular carcinoma 0/50, 0/50, 1/50, 6/50; hepatocellular adenoma or carcinoma 0/50, 0/50, 2/50, 6/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Mice |
B6C3F1/N |
Female |
Gavage |
Lung
|
Clear Evidence |
Clear Evidence |
alveolar/bronchiolar adenoma 2/50, 4/50, 8/50, 12/50; alveolar/bronchiolar adenoma or carcinoma 2/50, 5/50, 9/50, 13/50
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Female |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 1/49, 0/50, 2/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Nasal Cavity
|
Clear Evidence |
Clear Evidence |
transitional epithelium, adenoma 0/50, 3/49, 2/50, 11/49; transitional epithelium, adenoma or carcinoma 0/50, 3/49, 2/50, 13/49
|
Neoplastic Lesions
|
No
|
TR-579
|
99-97-8 |
N,N-Dimethyl-p-toluidine |
Rats |
F344/N |
Male |
Gavage |
Thyroid Gland Follicular Cell
|
Clear Evidence |
Equivocal Evidence |
adenoma or carcinoma 1/50, 2/49, 2/50, 4/49
|
May Have Been Related
|
Yes
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA 0/50 1/50 0/50 1/50
|
May Have Been Related
|
Yes
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Forestomach
|
Clear Evidence |
Equivocal Evidence |
SQUAMOUS CELL PAPILLOMA O/50 0/50 1/50 1/50; SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 1/50
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 14/50 11/50 14/50 26/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Hematopoietic System
|
Clear Evidence |
Clear Evidence |
MONONUCLEAR CELL LEUKEMIA 26/50 25/50 42/50 34/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) ADENOMATOUS POLYP 0/60 8/60 18/60, CARCINOMA 0/60 0/60 2/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Intestines (Large)
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) ADENOMATOUS POLYP 0/60 26/60 30/60, CARCINOMA 0/60 0/60 5/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) PAPILLOMA 0/60 0/60 1/60 OR CARCINOMA 0/60 0/60 1/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Transitional Cell
|
Clear Evidence |
Clear Evidence |
PAPILLOMA (STOP STUDY) 0/60 0/60 4/60 OR CARCINOMA 0/60 1/60 8/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Clear Evidence |
Equivocal Evidence |
ADENOMA 0/49 1/50 1/50 1/49 OR CARCINOMA 0/49 0/50 0/50 2/49
|
May Have Been Related
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Liver
|
Clear Evidence |
Clear Evidence |
ADENOMA 14/50 26/50 41/50 29/50; CARCINOMA 7/50 12/50 11/50 7/50; HEPATOBLASTOMA 0/50 3/50 17/50 9/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Some Evidence |
Some Evidence |
ADENOMA 14/50 2/50 36/50 18/50
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Female |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/58 2/59 1/60, TRANSITIONAL CELL CARCINOMA 0/58 28/59 48/60
|
Neoplastic Lesions
|
No
|
TR-416
|
91-23-6 |
o-Nitroanisole |
Rats |
F344/N |
Male |
Dosed-Feed |
Urinary Bladder
|
Clear Evidence |
Clear Evidence |
(STOP STUDY) TRANSITIONAL CELL PAPILLOMA 0/59 9/59 1/60, TRANSITIONAL CELL CARCINOMA 0/59 27/59 50/60, SQUAMOUS CELL PAPILLOMA 0/59 0/59 4/60, SQUAMOUS CELL CARCINOMA 0/59 0/59 6/60, SARCOMA 0/59 2/59 9/60
|
Neoplastic Lesions
|
No
|
TR-140
|
1955-45-9 |
Pivalolactone |
Mice |
B6C3F1 |
Female |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-140
|
1955-45-9 |
Pivalolactone |
Mice |
B6C3F1 |
Male |
Gavage |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-140
|
1955-45-9 |
Pivalolactone |
Rats |
F344/N |
Female |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-140
|
1955-45-9 |
Pivalolactone |
Rats |
F344/N |
Male |
Gavage |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-115
|
95-06-7 |
Sulfallate |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-115
|
95-06-7 |
Sulfallate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-115
|
95-06-7 |
Sulfallate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-115
|
95-06-7 |
Sulfallate |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Mammary Gland
|
Positive |
Positive |
(ADENOCARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Rats |
Osborne Mendel |
Female |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Rats |
Osborne Mendel |
Male |
Dosed-Feed |
Unspecified
|
Negative |
|
Not applicable
|
Not applicable
|
Yes
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-034
|
1582-09-8 |
Trifluralin |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA)
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Forestomach
|
Positive |
Positive |
(SQUAMOUS CELL PAPILLOMA, SQUAMOUS CELL PAPILLOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Female |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Rats |
F344/N |
Male |
Dosed-Feed |
Kidney Tubular Cell
|
Positive |
Positive |
ADENOMA, ADENOMA OR ADENOCARCINOMA
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Liver
|
Positive |
Positive |
(ADENOMA, CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Female |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA)
|
Neoplastic Lesions
|
No
|
TR-076
|
126-72-7 |
tris(2,3-Dibromopropyl) phosphate |
Mice |
B6C3F1 |
Male |
Dosed-Feed |
Lung
|
Positive |
Positive |
(ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA)
|
Neoplastic Lesions
|
Yes
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA 0/46 2/47 3/44 5/45
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/48 10/48 8/48 21/48 CARCINOMA 0/48 1/48 11/48 11/48 COMBINED 3/48 11/48 19/48 30/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
ADENOMA 3/47 11/47 25/47 28/47 CARCINOMA 0/47 1/47 7/47 16/47 COMBINED 3/47 12/47 30/47 38/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 1/47 5/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 1/47 7/47 ADENOMA 5/48 10/47 19/47 18/47 ADENOMA OR CARCINOMA 5/48 11/47 20/47 19/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 1/46 2/47 5/46 13/44 ADENOMA 7/46 13/47 17/46 17/44 ADENOMA OR CARCINOMA 12/46 18/47 24/46 23/44
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 6/48 17/48 29/47 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 4/48 13/48 19/47 COMBINED 6/48 8/48 28/48 39/47
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
ALVEOLAR/BRONCHIOLAR ADENOMA 4/48 17/48 22/47 34/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 1/48 9/47 9/48 COMBINED 5/48 18/48 29/47 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
ADENOACANTHOMA 0/47 1/46 1/46 11/48 ADENOCARCINOMA 4/47 3/46 3/46 11/48 COMBINED 4/47 4/46 4/46 22/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
BENIGN GRANULOSA CELL TUMOR 0/48 0/46 2/46 3/39 MALIGNANT GRANULOSA CELL TUMOR 0/48 0/46 0/46 3/39 COMBINED 0/48 0/46 2/46 5/39
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/48 0/46 2/48
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/47, 1/48, 5/47, 8/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/45 1/47 4/46
|
Neoplastic Lesions
|
No
|
TR-510
|
51-79-6 |
Urethane |
Mice |
MV |
Female |
Dosed-Water |
Uterus/Cervix
|
Clear Evidence |
Clear Evidence |
HEMANGIOSARCOMA 0/48 0/47 0/48 2/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 4/48 7/48 6/46 20/46 CARCINOMA 1/48 11/48 7/46 10/46 COMBINED 5/48 18/48 13/46 29/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 2/47 3/47 9/46 19/47 CARCINOMA 1/47 3/47 6/46 16/47 COMBINED 3/47 5/47 15/46 35/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOMA 6/48 14/48 21/47 27/48 CARCINOMA 0/48 0/48 1/47 16/48 COMBINED 6/48 14/48 21/47 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Harderian Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOMA 5/47 12/48 15/48 26/45 CARCINOMA 0/47 2/48 2/48 10/45 COMBINED 5/47 14/48 17/48 35/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 0/48 6/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 3/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/48 0/48 2/47 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Heart
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/47 0/48 1/48 4/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 0/48 0/47 0/48 6/48 ADENOMA 3/48 6/47 16/48 16/48 ADENOMA OR CARCINOMA 3/48 7/47 16/48 17/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 1/47 2/47 0/47 7/46 ADENOMA 6/47 5/47 15/47 23/46 ADENOMA OR CARCINOMA 7/47 5/47 16/47 23/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 3/47 4/48 3/46 11/48 ADENOMA 12/47 15/48 16/46 24/48 ADENOMA OR CARCINOMA 16/47 19/48 17/46 24/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) HEMANGIOSARCOMA 2/48 2/46 4/48 13/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 5/47 10/47 16/48 28/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 0/47 2/47 6/48 23/48 COMBINED 5/47 11/47 21/48 38/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 5/48 10/48 18/48 30/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 1/48 7/48 9/48 23/48 COMBINED 5/48 17/48 24/48 37/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADEMONA 6/48 8/48 9/48 33/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 5/48 4/48 5/48 17/48 COMBINED 11/48 11/48 14/48 40/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Lung
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ALVEOLAR/BRONCHIOLAR ADENOMA 10/48 16/48 19/47 35/48 ALVEOLAR/BRONCHIOLAR CARCINOMA 2/48 3/48 8/47 24/48 COMBINED 11/48 19/48 24/47 43/48
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) ADENOACANTHOMA 0/47 0/45 2/48 3/47 ADENOCARCINOMA 4/47 3/45 11/48 14/47 COMBINED 4/47 3/45 12/48 16/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Mammary Gland
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) ADENOACANTHOMA 0/47 0/48 1/48 9/45 ADENOCARCINOMA 3/47 4/48 6/48 15/45 COMBINED 3/47 4/48 7/48 23/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Ovary
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) BENIGN GRANULOSA CELL TUMOR 0/46 0/47 5/46 3/45 BENIGN OR MALIGNANT GRANULOSA CELL TUMOR 0/46 0/47 6/46 3/45
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/47 0/48 2/47
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 1/48, 4/46, 7/47)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Skin
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 5% ETHANOL) SQUAMOUS CELL PAPILLOMA OR SQUAMOUS CELL CARCINOMA (0/48, 2/47, 0/48, 7/48)
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Female |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/47 0/46 0/46 3/46
|
Neoplastic Lesions
|
No
|
TR-510
|
URETHCOMB |
Urethane + ethanol (combination) |
Mice |
MV |
Male |
Dosed-Water |
Spleen
|
Clear Evidence |
Clear Evidence |
(URETHANE AND 2.5% ETHANOL) HEMANGIOSARCOMA 0/46 0/46 1/46 3/46
|
Neoplastic Lesions
|
Yes
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Mice |
B6C3F1/N |
Female |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma 1/50 0/50 5/50 14/50
|
Neoplastic Lesions
|
Yes
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Forestomach
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 1/50 0/50 5/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Male |
Dosed-Water |
Glandular Stomach
|
Clear Evidence |
Clear Evidence |
Adenoma 0/50 0/50 0/50 2/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Mice |
B6C3F1/N |
Male |
Dosed-Water |
Liver
|
Clear Evidence |
Equivocal Evidence |
Hepatoblastoma 1/50 7/50 3/50 2/50 adenoma, carcinoma or hepatoblastoma 37/50 46/50 43/50 42/50
|
May Have Been Related
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Male |
Dosed-Water |
Oral Cavity
|
Clear Evidence |
Clear Evidence |
Squamous cell papilloma or carcinoma 0/50 0/50 2/50 5/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Female |
Dosed-Water |
Oral Cavity
|
Some Evidence |
Some Evidence |
Squamous cell papilloma 1/50 0/50 4/50 0/50
|
Neoplastic Lesions
|
No
|
TR-544
|
3252-43-5 |
Water disinfection byproducts (Dibromoacetonitrile) |
Rats |
F344/N |
Female |
Dosed-Water |
Skin
|
Some Evidence |
Equivocal Evidence |
Squamous cell papilloma, keratoacanthoma, basal cell adenoma or carcinoma 0/50 0/50 3/50 4/50
|
May Have Been Related
|